Cell2B is granted Orphan Medical Product Designation EU/3/14/1388 for Prevention of Graft-versus-Host Disease (GvHD) by the European Commission upon positive opinion by the Committee for Orphan Medicinal Products. This new designation comes on top of Orphan Designation for GvHD treatment granted in 2013 (EU/3/13/1129). Cell2B is strongly committed to deliver new therapies that tackle this unmet clinical need. GvHD is the lead indication of a larger set of immune indications Cell2B is addressing.
Cell2B Website (09.01.2015)
Cell2B appoints international advisory board | Cell2B
Cell2B is honored to make public our long term commitment with our Advisory Board . Charles Cooney (PhD), Duke Collier (JD), and Frederic Chereau (MBA) have been very active since Cell2B's incorporation.
The Rector Group (29.04.2014)
10 new companies to watch
5 months ago I’ve picked and brought to your attention a list of new interesting companies. In the last few months, I’ve learned more companies, and today, I’m sharing the new list of 10 with you.
Zeyton received a Seed Round of € 600.000
Shilling Capital Partners co-invested with other Business Angels.